Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Primary Myelofibrosis 39Myeloproliferative Disorders 30Leukemia, Myeloid, Acute 23Polycythemia Vera 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia 17Myelodysplastic Syndromes 15Thrombocythemia, Essential 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms 9Multiple Myeloma 9Graft vs Host Disease 9Breast Neoplasms 9Pancreatic Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Recurrence 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hematologic Neoplasms 6Prostatic Neoplasms 5Lymphoma, T-Cell 5Lymphoma 5Leukemia, Myeloid, Chronic-Phase 5Hodgkin Disease 5Hematologic Diseases 5Colorectal Neoplasms 5Thrombocytosis 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Carcinoma, Non-Small-Cell Lung 4

Interventions

pembrolizumab 162Carboplatin 144Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 38Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × ruxolitinib × Clear all
NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
23 enrolled 18 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Baylor Research Institute

Phase EARLY_PHASE1 Recruiting
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03012230 2024-01-31

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Mayo Clinic

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡